These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19178670)

  • 1. Dose-escalating vinblastine for the treatment of canine mast cell tumour.
    Vickery KR; Wilson H; Vail DM; Thamm DH
    Vet Comp Oncol; 2008 Jun; 6(2):111-9. PubMed ID: 19178670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.
    Taylor F; Gear R; Hoather T; Dobson J
    J Small Anim Pract; 2009 Jun; 50(6):284-9. PubMed ID: 19527421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997).
    Thamm DH; Mauldin EA; Vail DM
    J Vet Intern Med; 1999; 13(5):491-7. PubMed ID: 10499735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment: a retrospective study in fourteen dogs with mast cell tumours.
    Trumel C; Bourgès-Abella N; Touron C; Lanore D; Geffré A; Diquelou A; Guelfi JF; Braun JP
    J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):275-9. PubMed ID: 16050908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose escalation of single-agent vinblastine in dogs.
    Bailey DB; Rassnick KM; Kristal O; Chretin JD; Balkman CE
    J Vet Intern Med; 2008; 22(6):1397-402. PubMed ID: 19000250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases.
    Thamm DH; Turek MM; Vail DM
    J Vet Med Sci; 2006 Jun; 68(6):581-7. PubMed ID: 16820715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of vinblastine for treatment of canine mast cell tumors.
    Rassnick KM; Bailey DB; Flory AB; Balkman CE; Kiselow MA; Intile JL; Autio K
    J Vet Intern Med; 2008; 22(6):1390-6. PubMed ID: 19000249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
    Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
    J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
    Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
    Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs.
    Stanclift RM; Gilson SD
    J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
    Hahn KA; Legendre AM; Shaw NG; Phillips B; Ogilvie GK; Prescott DM; Atwater SW; Carreras JK; Lana SE; Ladue T; Rusk A; Kinet JP; Dubreuil P; Moussy A; Hermine O
    Am J Vet Res; 2010 Nov; 71(11):1354-61. PubMed ID: 21034327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.
    Cooper M; Tsai X; Bennett P
    Vet Comp Oncol; 2009 Sep; 7(3):196-206. PubMed ID: 19691648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.
    Weishaar KM; Ehrhart EJ; Avery AC; Charles JB; Elmslie RE; Vail DM; London CA; Clifford CA; Eickhoff JC; Thamm DH
    J Vet Intern Med; 2018 Jan; 32(1):394-405. PubMed ID: 29194765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs.
    Henry CJ; Downing S; Rosenthal RC; Klein MK; Meleo K; Villamil JA; Fineman LS; McCaw DL; Higginbotham ML; McMichael J
    Am J Vet Res; 2007 Nov; 68(11):1246-51. PubMed ID: 17975981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypotonic water as adjuvant therapy for incompletely resected canine mast cell tumors: a randomized, double-blind, placebo-controlled study.
    Brocks BA; Neyens IJ; Teske E; Kirpensteijn J
    Vet Surg; 2008 Jul; 37(5):472-8. PubMed ID: 18986315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).
    Lejeune A; Skorupski K; Frazier S; Vanhaezebrouck I; Rebhun RB; Reilly CM; Rodriguez CO
    Vet Comp Oncol; 2015 Sep; 13(3):267-80. PubMed ID: 23721492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival.
    Krick EL; Billings AP; Shofer FS; Watanabe S; Sorenmo KU
    Vet Comp Oncol; 2009 Jun; 7(2):130-8. PubMed ID: 19453367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine.
    Thamm DH; Weishaar KM; Charles JB; Ehrhart EJ
    Vet Comp Oncol; 2020 Jun; 18(2):169-175. PubMed ID: 31365175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
    Kiupel M; Webster JD; Miller RA; Kaneene JB
    J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.